Combination of known and unknown mechanisms confers high-level resistance to fluoroquinolones in Enterococcus faecium
- 1 June 2006
- journal article
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 55 (6) , 729-736
- https://doi.org/10.1099/jmm.0.46303-0
Abstract
In order to elucidate the mechanisms of fluoroquinolone resistance in Enterococcus faecium, spontaneous mutants isolated from Ent. faecium ATCC 19434 by stepwise selection with sparfloxacin (SPX) or norfloxacin (NOR) and 13 clinical isolates of Ent. faecium were characterized by analysing quinolone-resistance-determining regions (QRDRs) of the gyrA, gyrB, parC and parE genes and examining changes in MICs of SPX and NOR in the presence of efflux pump inhibitors. The SPX-selected first-step mutant had a point mutation only in gyrA, and the mutants QR7-18 and QR7-39, and clinical isolates that had point mutations in parC, showed NOR resistance. These results indicate that the primary targets of SPX and NOR are DNA gyrase and topoisomerase IV, respectively, and therefore that the primary target of fluoroquinolones in Ent. faecium differs depending on the structure of the compound used. The characterization of the spontaneous mutants and the clinical isolates demonstrates that in addition to the previously reported alterations in GyrA and ParC, an alteration in GyrB, a NorA-like pump, an unknown efflux pump, which excretes both SPX and NOR from bacterial cells, and probably other unknown mechanism(s) all contribute to fluoroquinolone resistance in Ent. faecium.Keywords
This publication has 35 references indexed in Scilit:
- Characterization of emeA , a norA Homolog and Multidrug Resistance Efflux Pump, in Enterococcus faecalisAntimicrobial Agents and Chemotherapy, 2001
- Association of Alterations in ParC and GyrA Proteins with Resistance of Clinical Isolates of Enterococcus faecium to Nine Different FluoroquinolonesAntimicrobial Agents and Chemotherapy, 1999
- Alterations in GyrA and ParC Associated with Fluoroquinolone Resistance in Enterococcus faeciumAntimicrobial Agents and Chemotherapy, 1999
- Effects of NorA Inhibitors on In Vitro Antibacterial Activities and Postantibiotic Effects of Levofloxacin, Ciprofloxacin, and Norfloxacin in Genetically Related Strains of Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 1999
- Identification of an Efflux Pump Gene, pmrA , Associated with Fluoroquinolone Resistance in Streptococcus pneumoniaeAntimicrobial Agents and Chemotherapy, 1999
- Inducible NorA-mediated multidrug resistance in Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 1995
- Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 1995
- Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 1994
- Factors influencing the accumulation of ciprofloxacin in Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 1989
- Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteersAntimicrobial Agents and Chemotherapy, 1985